AKT1 and prostate carcinoma: Specifically, knockdown of the splice variant CD44v6 in prostate cancer cell lines enhanced chemo-/radiosensitivity by downregulation of the PI3K/AKT/mTOR and Wnt/β-catenin signalling pathways [17].